Trial intelligence / Profile preview

Open-Label Extension Study of Zilucoplan in Generalized Myasthenia Gravis

jRCT2080225129Phase 3Completed

Sponsor
UCB
Start
Mar 2020
Modality
Cyclic Peptides → Modified Peptides → Peptides
01

Overview

Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Started Mar 2020; status: completed.

02

Drugs

zilucoplan
03

Conditions

myasthenia gravis (MG)

Beyond the preview

Go deeper on jRCT2080225129.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080225129.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call